Anti-Diabetes Drugs - Worldwide

Worldwide

The revenue in the Anti-Diabetes Drugs market worldwide is projected to reach €71.61bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 6.99%, resulting in a market volume of €100.40bn by 2029.
In global comparison, United States is anticipated to generate the highest revenue with €34,730.00m in 2024.
The global demand for anti-diabetes drugs is steadily increasing, with countries like the United States and China leading the way in terms of market growth.

Key regions: India, Australia, Italy, Europe, Brazil

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Diabetes Drugs market has been experiencing significant growth in recent years due to the increasing prevalence of diabetes worldwide.

Customer preferences: Customers are increasingly demanding more effective and convenient anti-diabetes drugs. They are also looking for drugs that have fewer side effects and are more affordable.

Trends in the market: In the US, the market for anti-diabetes drugs has been growing due to the rising incidence of diabetes and the availability of new drugs that are more effective than older ones. In Europe, the market has been growing due to the increasing demand for insulin and the availability of biosimilar insulin products. In Asia, the market has been growing due to the increasing prevalence of diabetes and the availability of affordable generic drugs.

Local special circumstances: In China, the market for anti-diabetes drugs has been growing due to the increasing prevalence of diabetes and the government's efforts to improve healthcare access. In India, the market has been growing due to the increasing awareness of diabetes and the availability of affordable generic drugs. In Brazil, the market has been growing due to the increasing demand for insulin and the government's efforts to improve healthcare access.

Underlying macroeconomic factors: The global economy has been growing, leading to increased healthcare spending and demand for anti-diabetes drugs. The aging population and unhealthy lifestyles have also contributed to the increasing prevalence of diabetes worldwide. Additionally, government initiatives to improve healthcare access and affordability have also played a role in the growth of the anti-diabetes drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.